Icotinib Versus Placebo as Adjuvant Therapy in EGFR-mutant Lung Adenocarcinoma
Status:
Unknown status
Trial end date:
2021-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare 3years of disease-free survival (DFS) of Icotinib and
placebo in the treatment of patients who EGFR mutation-positive II-IIIA lung adenocarcinoma.